世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

頭蓋内治療薬-世界市場シェアとランキング、全体売上高と需要予測 2025-2031

頭蓋内治療薬-世界市場シェアとランキング、全体売上高と需要予測 2025-2031


Intracranial Therapeutic- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

頭蓋内治療薬の世界市場は、2024年には100万米ドル規模になると推定され、2031年には100万米ドルに再調整され、予測期間2025-2031年の年平均成長率は%になると予測されている。 世界の医薬品市場は2022年に1,4... もっと見る

　

　

出版社 出版年月 電子版価格 納期 言語
QYResearch
QYリサーチ 		2025年3月21日 US$3,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		5-7営業日 英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

頭蓋内治療薬の世界市場は、2024年には100万米ドル規模になると推定され、2031年には100万米ドルに再調整され、予測期間2025-2031年の年平均成長率は%になると予測されている。

世界の医薬品市場は2022年に1,475億米ドルとなり、今後6年間のCAGRは5％で成長する。医薬品市場には、化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億米ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間＆政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン・マネジメントの重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調している。

本レポートは、頭蓋内治療薬の世界市場について、地域別・国別、タイプ別、用途別の分析とともに、総売上高、主要企業の市場シェア、ランキングを中心に包括的に紹介することを目的としています。
頭蓋内治療薬の市場規模、推計、予測は、2024年を基準年として、2020年から2031年までの期間の履歴データと予測データを売上高（百万ドル）で提供します。定量的、定性的な分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、頭蓋内治療薬に関する情報に基づいたビジネス上の意思決定を行うことを支援します。

市場区分
企業別
ノバルティスAG
バイオマリン
コレステム社
アラウノス・セラピューティクス社
アピックバイオ
ステメディカ・セル・テクノロジーズ社
ボイジャー・セラピューティクス
バイエル
アベオナ・セラピューティクス
スパーク・セラピューティクス
タイプ別セグメント
細胞ベース療法
遺伝子治療
酵素置換療法
用途別セグメント
脊髄性筋萎縮症（SMA）
多発性硬化症
バッテン病
筋萎縮性側索硬化症
地域別
北米
米国
カナダ
アジア太平洋
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア太平洋地域
ヨーロッパ
ドイツ
フランス
英国
イタリア
オランダ
北欧諸国
その他のヨーロッパ
ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ
中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
その他のMEA

各章の概要
第1章： レポートのスコープ、世界の総市場規模を紹介します。本章ではまた、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。
第2章：頭蓋内治療薬企業の競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。
第3章：各種市場セグメントをタイプ別に分析し、各市場セグメントの市場規模や発展可能性を網羅し、読者が各市場セグメントにおけるブルーオーシャン市場を見つけやすくします。
第4章：用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。
第5章：地域レベルでの頭蓋内治療薬の収益。各地域の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、将来の発展展望、市場空間、市場規模を紹介しています。
第6章：国別頭蓋内治療薬の収益。各国/地域のタイプ別、用途別のシグメイトデータを提供。
第7章：主要企業のプロフィールを提供し、製品収益、粗利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介します。
第8章：産業の上流と下流を含む産業チェーンの分析。
第9章：結論


ページTOPに戻る


目次

1 Market Overview
1.1 Intracranial Therapeutic Product Introduction
1.2 Global Intracranial Therapeutic Market Size Forecast (2020-2031)
1.3 Intracranial Therapeutic Market Trends & Drivers
1.3.1 Intracranial Therapeutic Industry Trends
1.3.2 Intracranial Therapeutic Market Drivers & Opportunity
1.3.3 Intracranial Therapeutic Market Challenges
1.3.4 Intracranial Therapeutic Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Intracranial Therapeutic Players Revenue Ranking (2024)
2.2 Global Intracranial Therapeutic Revenue by Company (2020-2025)
2.3 Key Companies Intracranial Therapeutic Manufacturing Base Distribution and Headquarters
2.4 Key Companies Intracranial Therapeutic Product Offered
2.5 Key Companies Time to Begin Mass Production of Intracranial Therapeutic
2.6 Intracranial Therapeutic Market Competitive Analysis
2.6.1 Intracranial Therapeutic Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Intracranial Therapeutic Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Intracranial Therapeutic as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Cell-based Therapy
3.1.2 Gene Therapy
3.1.3 Enzyme Replacement Therapy
3.2 Global Intracranial Therapeutic Sales Value by Type
3.2.1 Global Intracranial Therapeutic Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Intracranial Therapeutic Sales Value, by Type (2020-2031)
3.2.3 Global Intracranial Therapeutic Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Spinal Muscular Atrophy (SMA)
4.1.2 Multiple Sclerosis
4.1.3 Batten Disease
4.1.4 Amyotrophic Lateral Sclerosis
4.2 Global Intracranial Therapeutic Sales Value by Application
4.2.1 Global Intracranial Therapeutic Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Intracranial Therapeutic Sales Value, by Application (2020-2031)
4.2.3 Global Intracranial Therapeutic Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Intracranial Therapeutic Sales Value by Region
5.1.1 Global Intracranial Therapeutic Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Intracranial Therapeutic Sales Value by Region (2020-2025)
5.1.3 Global Intracranial Therapeutic Sales Value by Region (2026-2031)
5.1.4 Global Intracranial Therapeutic Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Intracranial Therapeutic Sales Value, 2020-2031
5.2.2 North America Intracranial Therapeutic Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Intracranial Therapeutic Sales Value, 2020-2031
5.3.2 Europe Intracranial Therapeutic Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Intracranial Therapeutic Sales Value, 2020-2031
5.4.2 Asia Pacific Intracranial Therapeutic Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Intracranial Therapeutic Sales Value, 2020-2031
5.5.2 South America Intracranial Therapeutic Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Intracranial Therapeutic Sales Value, 2020-2031
5.6.2 Middle East & Africa Intracranial Therapeutic Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Intracranial Therapeutic Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Intracranial Therapeutic Sales Value, 2020-2031
6.3 United States
6.3.1 United States Intracranial Therapeutic Sales Value, 2020-2031
6.3.2 United States Intracranial Therapeutic Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Intracranial Therapeutic Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Intracranial Therapeutic Sales Value, 2020-2031
6.4.2 Europe Intracranial Therapeutic Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Intracranial Therapeutic Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Intracranial Therapeutic Sales Value, 2020-2031
6.5.2 China Intracranial Therapeutic Sales Value by Type (%), 2024 VS 2031
6.5.3 China Intracranial Therapeutic Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Intracranial Therapeutic Sales Value, 2020-2031
6.6.2 Japan Intracranial Therapeutic Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Intracranial Therapeutic Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Intracranial Therapeutic Sales Value, 2020-2031
6.7.2 South Korea Intracranial Therapeutic Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Intracranial Therapeutic Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Intracranial Therapeutic Sales Value, 2020-2031
6.8.2 Southeast Asia Intracranial Therapeutic Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Intracranial Therapeutic Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Intracranial Therapeutic Sales Value, 2020-2031
6.9.2 India Intracranial Therapeutic Sales Value by Type (%), 2024 VS 2031
6.9.3 India Intracranial Therapeutic Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Novartis AG
7.1.1 Novartis AG Profile
7.1.2 Novartis AG Main Business
7.1.3 Novartis AG Intracranial Therapeutic Products, Services and Solutions
7.1.4 Novartis AG Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.1.5 Novartis AG Recent Developments
7.2 BioMarin
7.2.1 BioMarin Profile
7.2.2 BioMarin Main Business
7.2.3 BioMarin Intracranial Therapeutic Products, Services and Solutions
7.2.4 BioMarin Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.2.5 BioMarin Recent Developments
7.3 CORESTEM Inc.
7.3.1 CORESTEM Inc. Profile
7.3.2 CORESTEM Inc. Main Business
7.3.3 CORESTEM Inc. Intracranial Therapeutic Products, Services and Solutions
7.3.4 CORESTEM Inc. Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.3.5 CORESTEM Inc. Recent Developments
7.4 Alaunos Therapeutics, Inc.
7.4.1 Alaunos Therapeutics, Inc. Profile
7.4.2 Alaunos Therapeutics, Inc. Main Business
7.4.3 Alaunos Therapeutics, Inc. Intracranial Therapeutic Products, Services and Solutions
7.4.4 Alaunos Therapeutics, Inc. Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.4.5 Alaunos Therapeutics, Inc. Recent Developments
7.5 Apic Bio
7.5.1 Apic Bio Profile
7.5.2 Apic Bio Main Business
7.5.3 Apic Bio Intracranial Therapeutic Products, Services and Solutions
7.5.4 Apic Bio Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.5.5 Apic Bio Recent Developments
7.6 Stemedica Cell Technologies, Inc.
7.6.1 Stemedica Cell Technologies, Inc. Profile
7.6.2 Stemedica Cell Technologies, Inc. Main Business
7.6.3 Stemedica Cell Technologies, Inc. Intracranial Therapeutic Products, Services and Solutions
7.6.4 Stemedica Cell Technologies, Inc. Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.6.5 Stemedica Cell Technologies, Inc. Recent Developments
7.7 Voyager Therapeutics
7.7.1 Voyager Therapeutics Profile
7.7.2 Voyager Therapeutics Main Business
7.7.3 Voyager Therapeutics Intracranial Therapeutic Products, Services and Solutions
7.7.4 Voyager Therapeutics Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.7.5 Voyager Therapeutics Recent Developments
7.8 Bayer AG
7.8.1 Bayer AG Profile
7.8.2 Bayer AG Main Business
7.8.3 Bayer AG Intracranial Therapeutic Products, Services and Solutions
7.8.4 Bayer AG Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.8.5 Bayer AG Recent Developments
7.9 Abeona Therapeutics
7.9.1 Abeona Therapeutics Profile
7.9.2 Abeona Therapeutics Main Business
7.9.3 Abeona Therapeutics Intracranial Therapeutic Products, Services and Solutions
7.9.4 Abeona Therapeutics Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.9.5 Abeona Therapeutics Recent Developments
7.10 Spark Therapeutics
7.10.1 Spark Therapeutics Profile
7.10.2 Spark Therapeutics Main Business
7.10.3 Spark Therapeutics Intracranial Therapeutic Products, Services and Solutions
7.10.4 Spark Therapeutics Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.10.5 Spark Therapeutics Recent Developments
8 Industry Chain Analysis
8.1 Intracranial Therapeutic Industrial Chain
8.2 Intracranial Therapeutic Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Intracranial Therapeutic Sales Model
8.5.2 Sales Channel
8.5.3 Intracranial Therapeutic Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

　

ページTOPに戻る


　

Summary

The global market for Intracranial Therapeutic was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Intracranial Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Intracranial Therapeutic by region & country, by Type, and by Application.
The Intracranial Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Intracranial Therapeutic.

Market Segmentation
By Company
Novartis AG
BioMarin
CORESTEM Inc.
Alaunos Therapeutics, Inc.
Apic Bio
Stemedica Cell Technologies, Inc.
Voyager Therapeutics
Bayer AG
Abeona Therapeutics
Spark Therapeutics
Segment by Type
Cell-based Therapy
Gene Therapy
Enzyme Replacement Therapy
Segment by Application
Spinal Muscular Atrophy (SMA)
Multiple Sclerosis
Batten Disease
Amyotrophic Lateral Sclerosis
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Intracranial Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Intracranial Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Intracranial Therapeutic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.



ページTOPに戻る


Table of Contents

1 Market Overview
1.1 Intracranial Therapeutic Product Introduction
1.2 Global Intracranial Therapeutic Market Size Forecast (2020-2031)
1.3 Intracranial Therapeutic Market Trends & Drivers
1.3.1 Intracranial Therapeutic Industry Trends
1.3.2 Intracranial Therapeutic Market Drivers & Opportunity
1.3.3 Intracranial Therapeutic Market Challenges
1.3.4 Intracranial Therapeutic Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Intracranial Therapeutic Players Revenue Ranking (2024)
2.2 Global Intracranial Therapeutic Revenue by Company (2020-2025)
2.3 Key Companies Intracranial Therapeutic Manufacturing Base Distribution and Headquarters
2.4 Key Companies Intracranial Therapeutic Product Offered
2.5 Key Companies Time to Begin Mass Production of Intracranial Therapeutic
2.6 Intracranial Therapeutic Market Competitive Analysis
2.6.1 Intracranial Therapeutic Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Intracranial Therapeutic Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Intracranial Therapeutic as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Cell-based Therapy
3.1.2 Gene Therapy
3.1.3 Enzyme Replacement Therapy
3.2 Global Intracranial Therapeutic Sales Value by Type
3.2.1 Global Intracranial Therapeutic Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Intracranial Therapeutic Sales Value, by Type (2020-2031)
3.2.3 Global Intracranial Therapeutic Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Spinal Muscular Atrophy (SMA)
4.1.2 Multiple Sclerosis
4.1.3 Batten Disease
4.1.4 Amyotrophic Lateral Sclerosis
4.2 Global Intracranial Therapeutic Sales Value by Application
4.2.1 Global Intracranial Therapeutic Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Intracranial Therapeutic Sales Value, by Application (2020-2031)
4.2.3 Global Intracranial Therapeutic Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Intracranial Therapeutic Sales Value by Region
5.1.1 Global Intracranial Therapeutic Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Intracranial Therapeutic Sales Value by Region (2020-2025)
5.1.3 Global Intracranial Therapeutic Sales Value by Region (2026-2031)
5.1.4 Global Intracranial Therapeutic Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Intracranial Therapeutic Sales Value, 2020-2031
5.2.2 North America Intracranial Therapeutic Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Intracranial Therapeutic Sales Value, 2020-2031
5.3.2 Europe Intracranial Therapeutic Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Intracranial Therapeutic Sales Value, 2020-2031
5.4.2 Asia Pacific Intracranial Therapeutic Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Intracranial Therapeutic Sales Value, 2020-2031
5.5.2 South America Intracranial Therapeutic Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Intracranial Therapeutic Sales Value, 2020-2031
5.6.2 Middle East & Africa Intracranial Therapeutic Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Intracranial Therapeutic Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Intracranial Therapeutic Sales Value, 2020-2031
6.3 United States
6.3.1 United States Intracranial Therapeutic Sales Value, 2020-2031
6.3.2 United States Intracranial Therapeutic Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Intracranial Therapeutic Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Intracranial Therapeutic Sales Value, 2020-2031
6.4.2 Europe Intracranial Therapeutic Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Intracranial Therapeutic Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Intracranial Therapeutic Sales Value, 2020-2031
6.5.2 China Intracranial Therapeutic Sales Value by Type (%), 2024 VS 2031
6.5.3 China Intracranial Therapeutic Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Intracranial Therapeutic Sales Value, 2020-2031
6.6.2 Japan Intracranial Therapeutic Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Intracranial Therapeutic Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Intracranial Therapeutic Sales Value, 2020-2031
6.7.2 South Korea Intracranial Therapeutic Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Intracranial Therapeutic Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Intracranial Therapeutic Sales Value, 2020-2031
6.8.2 Southeast Asia Intracranial Therapeutic Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Intracranial Therapeutic Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Intracranial Therapeutic Sales Value, 2020-2031
6.9.2 India Intracranial Therapeutic Sales Value by Type (%), 2024 VS 2031
6.9.3 India Intracranial Therapeutic Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Novartis AG
7.1.1 Novartis AG Profile
7.1.2 Novartis AG Main Business
7.1.3 Novartis AG Intracranial Therapeutic Products, Services and Solutions
7.1.4 Novartis AG Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.1.5 Novartis AG Recent Developments
7.2 BioMarin
7.2.1 BioMarin Profile
7.2.2 BioMarin Main Business
7.2.3 BioMarin Intracranial Therapeutic Products, Services and Solutions
7.2.4 BioMarin Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.2.5 BioMarin Recent Developments
7.3 CORESTEM Inc.
7.3.1 CORESTEM Inc. Profile
7.3.2 CORESTEM Inc. Main Business
7.3.3 CORESTEM Inc. Intracranial Therapeutic Products, Services and Solutions
7.3.4 CORESTEM Inc. Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.3.5 CORESTEM Inc. Recent Developments
7.4 Alaunos Therapeutics, Inc.
7.4.1 Alaunos Therapeutics, Inc. Profile
7.4.2 Alaunos Therapeutics, Inc. Main Business
7.4.3 Alaunos Therapeutics, Inc. Intracranial Therapeutic Products, Services and Solutions
7.4.4 Alaunos Therapeutics, Inc. Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.4.5 Alaunos Therapeutics, Inc. Recent Developments
7.5 Apic Bio
7.5.1 Apic Bio Profile
7.5.2 Apic Bio Main Business
7.5.3 Apic Bio Intracranial Therapeutic Products, Services and Solutions
7.5.4 Apic Bio Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.5.5 Apic Bio Recent Developments
7.6 Stemedica Cell Technologies, Inc.
7.6.1 Stemedica Cell Technologies, Inc. Profile
7.6.2 Stemedica Cell Technologies, Inc. Main Business
7.6.3 Stemedica Cell Technologies, Inc. Intracranial Therapeutic Products, Services and Solutions
7.6.4 Stemedica Cell Technologies, Inc. Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.6.5 Stemedica Cell Technologies, Inc. Recent Developments
7.7 Voyager Therapeutics
7.7.1 Voyager Therapeutics Profile
7.7.2 Voyager Therapeutics Main Business
7.7.3 Voyager Therapeutics Intracranial Therapeutic Products, Services and Solutions
7.7.4 Voyager Therapeutics Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.7.5 Voyager Therapeutics Recent Developments
7.8 Bayer AG
7.8.1 Bayer AG Profile
7.8.2 Bayer AG Main Business
7.8.3 Bayer AG Intracranial Therapeutic Products, Services and Solutions
7.8.4 Bayer AG Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.8.5 Bayer AG Recent Developments
7.9 Abeona Therapeutics
7.9.1 Abeona Therapeutics Profile
7.9.2 Abeona Therapeutics Main Business
7.9.3 Abeona Therapeutics Intracranial Therapeutic Products, Services and Solutions
7.9.4 Abeona Therapeutics Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.9.5 Abeona Therapeutics Recent Developments
7.10 Spark Therapeutics
7.10.1 Spark Therapeutics Profile
7.10.2 Spark Therapeutics Main Business
7.10.3 Spark Therapeutics Intracranial Therapeutic Products, Services and Solutions
7.10.4 Spark Therapeutics Intracranial Therapeutic Revenue (US$ Million) & (2020-2025)
7.10.5 Spark Therapeutics Recent Developments
8 Industry Chain Analysis
8.1 Intracranial Therapeutic Industrial Chain
8.2 Intracranial Therapeutic Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Intracranial Therapeutic Sales Model
8.5.2 Sales Channel
8.5.3 Intracranial Therapeutic Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療）の最新刊レポート

QYResearch社の医療分野での最新刊レポート

本レポートと同じKEY WORD（demand）の最新刊レポート


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2025/04/01　10:27

150.82 円

163.67 円

197.69 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.